Compare TCX & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TCX | CMPX |
|---|---|---|
| Founded | 1992 | 2014 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 167.0M | 178.8M |
| IPO Year | 2005 | 2020 |
| Metric | TCX | CMPX |
|---|---|---|
| Price | $9.62 | $0.86 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 15 |
| Target Price | N/A | ★ $5.45 |
| AVG Volume (30 Days) | 49.1K | ★ 6.0M |
| Earning Date | 11-05-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $362,275,000.00 | N/A |
| Revenue This Year | $26.83 | N/A |
| Revenue Next Year | $10.04 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 6.76 | N/A |
| 52 Week Low | $8.45 | $0.83 |
| 52 Week High | $25.17 | $6.88 |
| Indicator | TCX | CMPX |
|---|---|---|
| Relative Strength Index (RSI) | 42.44 | 23.41 |
| Support Level | $8.62 | $0.83 |
| Resistance Level | $10.97 | $2.51 |
| Average True Range (ATR) | 0.52 | 0.08 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 34.50 | 14.66 |
Tucows Inc is a corporate parent, allocating capital and providing efficient shared services to its three businesses. The Company offers Mobile Service Enabler (MSE) solutions, as well as professional services to other retail mobile providers. The Company is also a distributor of Internet services, including domain name registration, digital certificates, and email. It provides these services through an Internet-based distribution network of Internet Service Providers, web hosting companies, and other providers of Internet services to end-users. It operates in three segments: Ting, Wavelo, and Tucows Domains. It generates the majority of its revenue from Tucows Domains. The company generates key revenue from Canada and USA.
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.